TTK Antibody (D-8): sc-376842

TTK Antibody (D-8) is a mouse monoclonal IgG1 kappa light chain antibody that detects TTK protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). anti-TTK antibody (D-8) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. TTK protein plays a crucial role in cell cycle regulation, particularly during the transition from G1 to S phase and peaking in G2 to M phase, where TTK is essential for proper cell division and proliferation. As a member of the serine-threonine/tyrosine family of protein kinases, TTK is expressed in a wide range of proliferating human cells and tissues, with TTK expression significantly reduced or absent in resting cells or those with a low proliferative index. Cloning of the full-length TTK sequence from a human T cell expression library using anti-phosphotyrosine antibodies, along with isolation of TTK mouse homolog from an embryonal carcinoma cell line, underscores TTK importance in cellular processes. Increase in TTK mRNA, protein, and kinase activity during cell cycle progression suggests TTK is a vital component in cell division regulation, making TTK (D-8) antibody an invaluable tool for researchers studying cell cycle dynamics and related pathways.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TTK Antibody (D-8) References:

1. Multiple cDNAs encoding the esk kinase predict transmembrane and intracellular enzyme isoforms.  |  Douville, EM., et al. 1992. Mol Cell Biol. 12: 2681-9. PMID: 1375325
2. Expression of TTK, a novel human protein kinase, is associated with cell proliferation.  |  Mills, GB., et al. 1992. J Biol Chem. 267: 16000-6. PMID: 1639825
3. TTK activates Akt and promotes proliferation and migration of hepatocellular carcinoma cells.  |  Liu, X., et al. 2015. Oncotarget. 6: 34309-20. PMID: 26418879
4. TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer.  |  Liu, Y., et al. 2021. J Ovarian Res. 14: 128. PMID: 34598710
5. TTK predicts triple positive breast cancer prognosis and regulates tumor proliferation and invasion.  |  Gao, YH., et al. 2022. Neoplasma. 69: 274-282. PMID: 34846157
6. FOXM1 Contributes to Chemotherapy Sensitivity in Cervical Cancer by Regulating TTK.  |  Tang, Q., et al. 2023. Discov Med. 35: 208-220. PMID: 37272088
7. TTK inhibition activates STING signal and promotes anti-PD1 immunotherapy in breast cancer.  |  Hu, X., et al. 2024. Biochem Biophys Res Commun. 694: 149388. PMID: 38150917
8. Ordering S phase and M phase in the cell cycle.  |  Nurse, P. 1994. Cell. 79: 547-50. PMID: 7954820
9. G1 phase progression: cycling on cue.  |  Sherr, CJ. 1994. Cell. 79: 551-5. PMID: 7954821
10. Mitosis in transition.  |  King, RW., et al. 1994. Cell. 79: 563-71. PMID: 7954823
11. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age.  |  Hunter, T. and Pines, J. 1994. Cell. 79: 573-82. PMID: 7954824
12. Cell cycle dependent regulation of the protein kinase TTK.  |  Hogg, D., et al. 1994. Oncogene. 9: 89-96. PMID: 8302607

The preferred TTK antibody is TTK Antibody (N1): sc-56968.